Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Gabriella McCarty

NP-C

Gabriella McCarty is a gastroenterology/hepatology nurse practitioner. She obtained her masters and nurse practitioner degree at Case Western Reserve University in 2004. She has been practicing in this field for 26 years. She serves as faculty for Gastroenterology/ Hepatology Advanced Practice Providers (GHAPP) and is an American College of Gastroenterology (ACG) committee member, serving on the education subcommittee. She will be completing her doctorate of nursing in May 2025. She loves all aspects of GI / Hepatology, education and nursing.

play

Alison Moe

PA-C

Alison S. Moe, MS, PA-C, is a board-certified physician assistant specializing in gastroenterology at United Digestive's Braselton office in Hoschton, Georgia. She earned her Master of Science in Medical Education from Seton Hall University and a Bachelor of Arts in Physical Anthropology from the State University of New York at Stony Brook. Alison is fluent in Spanish and has a special interest in treating irritable bowel syndrome and liver disease. With almost two decades of experience as a Physician Assistant, Alison has developed a strong foundation in both clinical practice and research, particularly in the fields of gastroenterology and hepatology. Alison's dedication to patient care includes extensive clinical hours, allowing her to cultivate deep relationships with patients as well as national experts caring for individuals, especially those suffering from inflammatory bowel disease (IBD) and advanced liver disease. Alison's commitment to advancing the understanding and treatment of these conditions drives my clinical practice and ongoing research efforts, aiming to provide the highest standard of care for my patients.

play

Christie Morrison

AGACNP-BC

Christie Morrison is a Board Certified Adult Advanced Practice Nurse and Lead APP at Oshi Health, a digital digestive health practice and IBD APP at Texas Digestive Disease Consultants in San Antonio, Texas. She strives to improve the lives of patients with chronic gastrointestinal conditions through a multidisciplinary approach. She has worked in various roles as a GI advanced practice provider, including inpatient, outpatient clinic, and telehealth since 2015. Mrs. Morrison is currently an active member of the American College of Gastroenterology where she is serving on the Editorial Board. She is also a member of several GI societies, including TSGE, AGA, ASGE, and GHAPP. Christie was recently honored with the ACG APP Clinical Excellence Award for community practice. She collaborates with industry partners and GI colleagues to enhance education and engagement for APPs working in Gastroenterology. She strives to improve the quality of life and better patient outcomes in all chronic GI conditions and believes that providing resources to her peers through education can help her achieve this goal.

MASLD/MASH Learning Center

Latest News & Blogs

Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States

August 2025

CONCLUSION: The use of cT1 to assign and monitor resmetirom treatment improves treatment allocation and reduces health system cost vs VCTE and liver biopsy.

Read More arrow

Non-Invasive Tests: Establishing efficacy for metabolic dysfunction associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food and Drug Administration

August 2025

To support drug development for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, multiple stakeholders including patients, clinicians, and investigators have communicated a desire to move away from liver histology. FDA accelerated approval is based on a surrogate endpoint (such as liver histology) that has less definitive evidence tying it to the clinical endpoint (such as death or liver transplant) but nonetheless is considered reasonably likely to predict clinical benefit...

Read More arrow

CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis

August 2025

CONCLUSIONS: Our findings reveal a novel role for CD44 in regulating the dynamics of group 1 ILCs, which in turn affects steatohepatitis and MASLD development.

Read More arrow

Application of machine learning and deep learning in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

August 2025

CONCLUSIONS: Both ML and DL models demonstrated strong diagnostic performance for MASH and liver fibrosis, with DL achieving marginally higher AUROCs. AI-driven approaches show promise in MASLD management.

Read More arrow

New Names, New Drugs, Better Outcomes in Steatotic Liver Disease

August 2025

Steatotic liver disease (SLD) is a growing cause of chronic liver disease, with potential progression to cirrhosis, hepatocellular carcinoma (HCC), and liver failure. Previously known as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new terminology, including metabolic-dysfunction associated steatotic liver disease (MASLD) and metabolic-dysfunction associated steatohepatitis (MASH), was introduced to improve diagnostic clarity and reduce stigmatization....

Read More arrow

Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of metabolic syndrome. Hepatic lipotoxicity and inflammation are two key factors driving progression of steatosis to metabolic dysfunction-associated steatohepatitis (MASH). The presence of MASH increases the risk of cardiovascular events, cirrhosis, hepatocellular carcinoma (HCC) and non-liver malignancies. Although MASLD and lipid species have been extensively examined in persons with type 2 diabetes,...

Read More arrow

Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

August 2025

BACKGROUND: ION224, a liver-directed antisense inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2), suppresses de novo lipogenesis, an important metabolic pathway associated with lipotoxicity and the underlying inflammation, hepatocellular injury, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to prospectively assess the safety and efficacy of ION224 in patients with MASH and fibrosis.

Read More arrow

Fibroblast growth factor receptor inhibitors ameliorate metabolic dysfunction-associated steatohepatitis by modulating the glycine-glutathione-gut microbiota axis

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease characterized by hepatic steatosis, inflammation, and fibrosis. Dysregulation of fibroblast growth factor receptor (FGFR) signaling is closely associated with various liver diseases, but its role in hepatic metabolism remains unclear. In this study, we developed a small-molecule FGFR inhibitor, CP0813, and evaluated its therapeutic potential in three diet-induced MASH mouse models. Using multi-omics analyses...

Read More arrow

Delineating unique MASH-endothelial cells in metabolic dysfunction-associated steatotic liver disease using single-cell lensing

August 2025

CONCLUSIONS: In summary, our study delineates the unique features of MASH-EC, enhancing our understanding of endothelial cell dysfunction in MASLD and laying the groundwork for future investigations into targeted therapeutic strategies.

Read More arrow

Peroxynitrite is key to Cylindrospermopsin-mediated MASLD to MASH progression via triggering TXNIP binding to NLRP3 and subsequent inflammasome activation

August 2025

Harmful algal bloom (HAB) toxins are shown to be associated with Metabolic dysfunction-associated steatohepatitis (MASH) progression. Several studies link the HAB toxin microcystin to hepatic inflammasome activation, but the role of cylindrospermopsin (CYN) in Metabolic dysfunction-associated steatotic liver disease (MASLD) pathology remains unknown. Using a mouse model of MASLD, we show that CYN exposure served as a second hit for MASLD to MASH progression, as shown by histopathology and NAS...

Read More arrow

A novel multi-parameter MRI-based model for identification of high-risk metabolic dysfunction-associated steatohepatitis

August 2025

CONCLUSION: The novel EFT1 model demonstrates reasonable performance in non-invasive identification of high-risk MASH patients compared to other models, achieving an appropriate balance between sensitivity and specificity.

Read More arrow

Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis

August 2025

Increased mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) imposes an urgent need to elucidate the pathogenesis of MASLD so that novel therapeutic strategies may be identified. Here, we delineate the mechanism of microRNA-34a-5p (miR-34a) in the progressive liver injury of MASLD and liver fibrosis. Specifically, liver tissue from patients with obesity-associated hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis, as...

Read More arrow

MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a significant public health issue worldwide, with a pronounced impact in India due to the escalating rates of obesity and type 2 diabetes mellitus (T2DM) driving its prevalence. This condition spans a range of hepatic disorders, from uncomplicated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), accompanied by differing levels of hepatic...

Read More arrow

FATP5 Deficiency Alleviates MASH via Remodeling Hepatic Lipid Composition to Suppress Ferroptosis

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) represents an advanced stage of fatty liver disease characterized by hepatocyte ballooning, cell death, inflammation and fibrosis. Fatty acid transport protein 5 (FATP5), a hepatocyte-specific transmembrane protein, mediates both long-chain fatty acids (LCFAs) uptake and bile acids (BAs)-coenzyme A (CoA) conjugation. While FATP5 upregulation has been documented in MASH patients, its functional role in disease progression through hepatic...

Read More arrow

Celastrol ameliorates metabolic dysfunction associated steatohepatitis by regulating the CYP7B1-mediated alternative bile acid synthetic pathway

August 2025

CONCLUSION: Our study demonstrated CEL as a novel MASH therapeutic that uniquely targets the FXR/LXR-CYP7B1 axis to reactivate the alternative BA synthetic pathway, providing a mechanistic basis for CEL in MASH intervention.

Read More arrow

Mechanism of Lipi Jiangzhuo Decoction in Improving Metabolic Dysfunction-Associated Steatohepatitis Through the PERK/PINK1/GPx4 Pathway

August 2025

CONCLUSION: LPJZD can improve MASH by regulating ER stress-mitophagy -ferroptosis axis in liver cells. The role of LPJZD in anti-inflammatory therapy provides new insights for the clinical prevention and treatment of MASH.

Read More arrow

More Than Just Bone Pain: A Case of Paget's Disease, Seropositive Rheumatoid Arthritis, and Metabolic Dysfunction-Associated Steatohepatitis (MASH) in a Patient With Elevated Alkaline Phosphatase (ALP)

August 2025

Paget's disease of bone is a chronic skeletal disorder characterized by disorganized bone remodeling. Although often asymptomatic, it is frequently first detected through elevated alkaline phosphatase (ALP). Given ALP's nonspecific nature, its elevation requires a comprehensive evaluation for hepatic, biliary, and bone pathology. We present a diagnostic challenge involving persistent ALP elevation in a patient ultimately found to have coexisting Paget's disease, metabolic dysfunction-associated...

Read More arrow

Identification of foam cell like M2 macrophages, AEBP1 biomarkers, and resveratrol as potential therapeutic in MASLD using Ecotyper and WGCNA

August 2025

The immune cell landscapes in metabolic dysfunction-associated fatty liver disease (MAFLD) and their clinical relevance have not been explored. We used Ecotyper to identify immune cell states based on gene expression and examined their roles in metabolic dysfunction-associated steatotic liver disease (MASLD) progression. Limma was applied to identify differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) was used for module identification. Bidirectional...

Read More arrow

miR-210-3p Ameliorates Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis by Targeting ISCU and Induces Ferroptosis

August 2025

CONCLUSIONS: miR-210-3p expression is decreased in MASH-related fibrosis and is involved in ferroptosis by targeting ISCU.

Read More arrow